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Abstract
Background. The relationship between cannabis use and psychosis is still a matter for debate.
Accounting for the individual differences in subjective experiences to recreational cannabis use in the
general population may hold some clues to the aetiological relationship between cannabis and psychotic
symptoms. We hypothesized that schizotypy would account for the individual differences in subjective
experiences after cannabis use but not in patterns of use. Method. In a sample of 532 young people who
had used cannabis at least once, we examined the relationship between the Cannabis Experiences
Questionnaire (CEQ) and the Schizotypal Personality Questionnaire (SPQ). Additionally, we examined the
psychometric properties of the CEQ. Results. We replicated our previously reported findings that
schizotypy was associated with increased psychosis-like experiences and after-effects, but also found
that high-scoring schizotypes reported more pleasurable experiences when smoking cannabis. Using new
subscales derived from principal components analysis (PCA), we found that the psychosis-like items
were most related to varying rates of schizotypy both during the immediate use of cannabis and in the
after-effects of cannabis use. High-scoring schizotypes who used cannabis experienced more psychosislike symptoms during and after use.Conclusions. Our results suggest that cannabis use may reveal an
underlying vulnerability to psychosis in those with high schizotypal traits.
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O R I G I N AL A R T IC L E

Schizotypy and psychosis-like experiences from
recreational cannabis in a non-clinical sample
E. Barkus and S. Lewis*
The University of Manchester, Manchester, UK

Background. The relationship between cannabis use and psychosis is still a matter for debate. Accounting for the
individual diﬀerences in subjective experiences to recreational cannabis use in the general population may hold some
clues to the aetiological relationship between cannabis and psychotic symptoms. We hypothesized that schizotypy
would account for the individual diﬀerences in subjective experiences after cannabis use but not in patterns of use.
Method. In a sample of 532 young people who had used cannabis at least once, we examined the relationship between
the Cannabis Experiences Questionnaire (CEQ) and the Schizotypal Personality Questionnaire (SPQ). Additionally, we
examined the psychometric properties of the CEQ.
Results. We replicated our previously reported ﬁndings that schizotypy was associated with increased psychosis-like
experiences and after-eﬀects, but also found that high-scoring schizotypes reported more pleasurable experiences when
smoking cannabis. Using new subscales derived from principal components analysis (PCA), we found that the psychosis-like items were most related to varying rates of schizotypy both during the immediate use of cannabis and in the
after-eﬀects of cannabis use. High-scoring schizotypes who used cannabis experienced more psychosis-like symptoms
during and after use.
Conclusions. Our results suggest that cannabis use may reveal an underlying vulnerability to psychosis in those with
high schizotypal traits.
Received 7 February 2007 ; Revised 6 December 2007 ; Accepted 6 December 2007 ; First published online 21 January 2008
Key words : Cannabis, psychosis proneness, schizotypy.

Introduction
In patients with established schizophrenia, recreational cannabis use has been reported to increase
relapse and symptom severity (Linszen et al. 1994 ;
Baigent et al. 1995). In addition, administration of
the principal psychoactive substance in cannabis, D9tetrahydrocannabinol (D9-THC), transiently exacerbates the positive, negative and cognitive symptoms
in stabilized patients with schizophrenia (D’Souza
et al. 2005).
There is also evidence that cannabis use is a risk
factor for the initial onset of psychosis. In a longitudinal community study, van Os et al. (2002) demonstrated that baseline cannabis use predicted the
emergence of psychotic symptoms and need for care
due to psychotic symptoms at follow-up. A recent review of the longitudinal studies to date reported that
regular cannabis seems to increase the risk of developing schizophrenia (Degenhardt & Hall, 2006).
* Address for correspondence : Professor S. Lewis, University of
Manchester, University Place (3rd ﬂoor East), Oxford Road,
Manchester M13 9PL, UK.
(Email : shon.lewis@manchester.ac.uk)

However, these studies do not determine the nature
of the relationship between cannabis and psychosis :
are those who are psychosis prone attracted to using
cannabis (an association model), does cannabis use
directly increase proneness to psychosis (a causal
model), or is there another factor that links psychosis
proneness and cannabis use (an indicator-variable
model ; Dumas et al. 2002)? A number of reviews have
tried to address the evidence for causal and association models (e.g. Hall et al. 2004 ; Verdoux et al. 2005 ;
Degenhardt & Hall, 2006 ; Fergusson et al. 2006).
The conclusion reached by authors on the basis
of current data is that, in individuals with an underlying predisposition to psychosis, cannabis use may
precipitate a psychotic episode, but it is diﬃcult to
argue for a direct and large causal role for cannabis
use in psychosis. However, Ferdinand et al. (2005) also
highlight the possibility that the nature of the relationship between cannabis use and psychotic symptoms may be bidirectional. This is a conclusion that
could be reached by most association studies, particularly those that do not attempt to control for baseline levels of psychotic symptoms or psychosis
proneness.
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One way to explore the relationship between psychotic symptoms and cannabis use is to examine the
impact of cannabis use in healthy individuals with psychometrically deﬁned psychosis proneness, or schizotypy. Schizotypal trait has been reported to be higher
in relatives of patients with schizophrenia (e.g. Appels
et al. 2004), may share some of the same risk genetic
loci as schizophrenia (Fanous et al. 2007) and may also
lead to increased cognitive deﬁcits in relatives of
patients with schizophrenia (Diwadkar et al. 2006).
Schizotypy is characterized by attenuated psychotic
symptoms that comprise both positive (unusual beliefs
and perceptual experiences) and negative (social
anxiety and withdrawal) features. Pre-existing schizotypy has been reported to increase the risk of psychotic
states from cannabis use (Henquet et al. 2005) and also
modulate sensitivity to the eﬀects of D9-THC (Henquet
et al. 2006). Although cannabis use per se has been reported to increase schizotypy scores (Kwapil et al.
1996 ; Williams et al. 1996 ; Moss et al. 2001 ; Skosnik et al.
2001 ; Dumas et al. 2002), these results have not been
consistent (Schiﬀman et al. 2005 ; Earleywine, 2006).
An alternative and perhaps more ecologically valid
approach is to examine the experiences that individuals report after using cannabis rather than placing
any emphasis on full psychotic syndromes. Henquet
et al. (2006) and D’Souza et al. (2004) tested the eﬀects
of D9-THC in healthy individuals ; however, D9-THC is
only one component of cannabis, and other ingredients
may be involved in the recreational eﬀects of cannabis.
In addition, the eﬀects of cannabis may be environmentally modulated and administration of the D9THC in a controlled and artiﬁcial environment may
not produce the same eﬀects as when it is used naturalistically. This naturalistic approach has been taken
in two previous studies. First, Verdoux et al. (2003)
used experience sampling, a method of charting subjective experience at random points during the day to
demonstrate that those with high psychosis vulnerability (deﬁned by a structured interview) were more
likely than those with low psychosis proneness to
report unusual perceptual experiences and thoughts
following recreational cannabis use. Second, we
have previously reported an association between high
schizotypy score, a measure of psychosis proneness,
and recreational cannabis-induced psychosis-like experiences and subsequent ‘after-eﬀects ’, using the
newly developed Cannabis Experiences Questionnaire
(CEQ ; Barkus et al. 2006). Given that there are individual diﬀerences in people’s self-reported responses
to cannabis, it is important to try to determine the
possible mechanisms that may underpin these diﬀerences in experience ; particularly as it is becoming clear
that individuals diﬀer in their risk for experiencing
psychotic symptoms following cannabis.

The current study aimed to replicate the ﬁndings of
Barkus et al. (2006) in a larger sample and also to reﬁne
the psychometric properties of the CEQ. Speciﬁcally,
we were interested in comparing the eﬀects of extreme
schizotypy scores on experiences from cannabis use.
We hypothesized (i) that schizotypy score would not
be related to patterns of cannabis use in terms of
whether used or not, age at ﬁrst use, or frequency of
use, but that (ii) individuals with high schizotypy
scores would report increased levels of psychosis-like
symptoms and subsequent after-eﬀects with cannabis
use compared to mean- or low-scoring schizotypes.
Method
Participants
Participants were drawn from a sample of 760 university students [mean age 22 (S.D.=4) years ; males
38 %] recruited using electronic advertisements either
emailed to them or as pop-up messages when they
logged onto their university system. The sample for
this study comprised 532 university students who reported they had used cannabis at least once in their
lifetime. A total of 49.7 % of the sample were current
users of cannabis, while 50.3 % classed themselves as
past users of cannabis. The frequency of cannabis use
for the whole sample was : once or twice only 13.4 % ;
no more than a few times each year 22 % ; at least once
a month 12.6 % ; at least once a week 27.2 %, and every
day 24.9 %. The majority of the participants smoked
cannabis during the evening (82.4 %), while 14.6 %
smoked cannabis frequently during the day and night,
and only 3.1 % reported smoking cannabis only during
the day. Other drugs used by participants are displayed in Table 1. Participants were completing a
variety of undergraduate or postgraduate studies at
one of three universities in North-West England.
Participants were not asked about psychiatric diagnosis or previous mental health problems.
Measures
Schizotypy (psychosis proneness)
Participants completed the Schizotypal Personality
Questionnaire (SPQ ; Raine, 1991) online. The questionnaire is based on the diagnostic criteria for schizotypal personality disorder and produces a total score
and scores on three dimensions : Cognitive Perceptual
(CP), Interpersonal (I) and Disorganized (D).
Cannabis Experiences Questionnaire (CEQ ; Barkus
et al. 2006)
The CEQ is a 55-item self-report scale that is divided
into three subscales. The Pleasurable Experiences
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(18 items) and Psychosis-Like Experiences subscales
(25 items) examine immediate responses to cannabis
and an After-Eﬀects subscale once the initial ‘ high’
from the cannabis has abated (12 items). Participants
indicated how frequently they had had the experiences on the CEQ by responding on a ﬁve-point scale
(Rarely or never, From time to time, Sometimes Yes
Sometimes No, More often than not, Almost always or
always). The frequency of cannabis use and age at ﬁrst
use were also assessed.
Procedure
Participants were initially contacted using remote
means (either email or pop-up message). The initial
recruitment email requested participants to take part
in research addressing personality, unusual experiences and cannabis use. The recruitment email stated
that the researchers wanted both cannabis and noncannabis users to approach the web page. Participants
approached the web-mounted SPQ and CEQ questionnaires under their own volition. All participants
completed the SPQ ﬁrst, and then followed with details of previous drug use before completing the CEQ.
Participants completed the questionnaires in their own
time, under conditions determined by the participant ;
no researchers were present at the time participants
completed the questionnaires. Participants were told
that the information they provided would be anonymous and conﬁdential and collected for research purposes only. Participants were not paid to complete the
questionnaires. The questionnaires were used as the
recruitment for a multi-staged study so participants
were asked to provide an email address. They were
provided with the ﬁrst author’s email address for any
questions that they had. Participants were able to give
informed consent and were told that by submitting
their results they were agreeing to the use and storage
of their responses.
Statistical analysis
The results were analysed using SPSS version 12 (SPSS
Inc., Chicago, IL, USA). A conservative Bonferroni approach to signiﬁcance levels was taken, where multiple tests were used to examine a research question.
The required signiﬁcance level to be reached and the
sample size used are stated separately for each analysis. The normality of the data was assessed by examining histograms, skewness and kurtosis ﬁgures.
For the group analysis where there were two groups,
t tests were used, and for group diﬀerences with three
groups, independent variable ANOVAs were used.
Taking a conservative approach, Scheﬀé post-hoc comparisons were performed to determine which groups
were signiﬁcantly diﬀerent from one another.
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The subscales for the CEQ reported in the paper by
Barkus et al. (2006) were produced on the basis of face
validity rather than statistical analysis. Therefore, to
determine the structure of the questionnaire items
from a statistical perspective, principal components
analysis (PCA) was used. A scree plot was used to
determine the number of components or factors to be
extracted from the data. An oblimin rotation was used
because conceptually we would expect the experiences
to be related to one another. Cronbach’s a coeﬃcient
was used to determine the internal consistency of the
items for the new subscales, with a value of 0.7 being
considered adequate.
Results
Patterns of cannabis and drug use and schizotypy
There was no relationship between frequency of cannabis use and scores on the SPQ for the total score or
the subscales. There was no relationship between age
of ﬁrst cannabis use and SPQ total. The relationship
between having smoked cannabis and current/past
cannabis use and psychosis proneness were examined
using independent t tests ; the Bonferroni-corrected
signiﬁcance value required to be reached to qualify for
signiﬁcance was 0.013. Participants who had smoked
cannabis at least once (n=532) had a higher mean score
on the Disorganized dimension from the SPQ than
those who had not (n=228) [t=4.05, df=758, p<0.001 ;
had smoked cannabis : 7.36 (S.D.=4.10) ; had not
smoked cannabis : 6.03 (S.D.=4.24)]. Additionally, there
was a trend for participants who described themselves
as current (rather than past) cannabis users (n=263) to
have higher scores on the Disorganization dimension
than those who had stopped smoking cannabis
(n=266) [t=2.40, df=527, p=0.017 ; past smokers :
6.96 (S.D.=4.05) ; current smokers : 7.81 (S.D.=4.08)].
To determine whether there was a relationship between other recreational drugs used by participants
and schizotypy score, the eﬀects of use of the drugs
displayed in Table 1 on schizotypy score were investigated. In line with correction for multiple comparisons, the signiﬁcance level to be reach for these
analyses was 0.005. There was only a signiﬁcant eﬀect
upon the Disorganized dimension for speed [t=2.86,
df=758, p=0.004 ; users : 7.98 (S.D.=4.01) ; non-users :
6.78 (S.D.=4.19)] and cocaine [t=2.80, df=758,
p=0.005 ; users : 7.72 (S.D.=4.11) ; non-users : 6.73
(S.D.=4.18)].
Schizotypy score and Barkus et al. (2006) cannabis
experiences
Participants were divided into three groups according
to their total SPQ score : more than 1 S.D. above the
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Table 1. The use of other recreational drug and alcohol in the sample

Alcohol

Speed

Cocaine

Ecstasy

Mushrooms

Tobacco

LSD

Age ﬁrst use,
mean (S.D.)

Ever
used ( %)

Current
users ( %)

14 (2.26)

81

95

17.61 (2.03)

18.83 (2.53)

18.33 (2.92)

18 (2.13)

14.63 (2.61)

17.34 (2.05)

15

23

26

18

11.2

7

2

38

38

36

64

2

Frequency ( %)

When used ( %)

Only once or twice
About once a year
A few times each year

1.1
0.6
3.1

About once a month
About once a week
More than once a week
Every day

8.3
24
50.3
12.5

Only once or twice
About once a year
A few times each year

38.8
7.8
25

About once a month
About once a week
More than once a week
Every day

14.7
5.2
5.2
3.4

Only once or twice
About once a year
A few times each year

30.6
3.3
33.9

About once a month
About once a week
More than once a week
Every day

21.1
7.8
1.7
1.7

Only once or twice
About once a year
A few times each year

18.5
5
33.5

About once a month
About once a week
More than once a week

23.5
13.5
6

Only once or twice
About once a year
A few times each year

35.3
11
47.8

About once a month
About once a week
More than once a week

4.4
0.7
0.7

Only once or twice
A few times each year
About once a month

3.5
1.2
5.8

About once a week
More than once a week
Every day

7
15.1
67.4

Only once or twice
About once a year
A few times each year

28.6
16.1
37.5

About once a month
About once a week
More than once a week

12.5
3.6
1.8

During the evening
During the day
Frequently during
the day and night

94.1
0.2
5.7

During the evening
During the day
Frequently during
the day and night

88.8
2.6
8.6

During the evening
During the day
Frequently during
the day and night

96.1
0.6
3.4

During the evening
During the day
Frequently during
the day and night

25.5
0.7
0.1

During the evening
During the day
Frequently during
the day and night

67.6
25.7
6.6

During the evening
During the day
Frequently during
the day and night

23.5
14.1
62.4

During the evening
During the day
Frequently during
the day and night

71.4
21.4
7.1

Schizotypy and psychosis-like experiences with cannabis use
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Table 1 (cont.)
Age ﬁrst use,
mean (S.D.)
Solvents

Poppers

14.71 (2.14)

16.34 (2.22)

Ever
used ( %)
0.9

4

Current
users ( %)
0

39

Frequency ( %)

When used ( %)

Only once or twice
A few times each year
About once a week

28.6
14.3
28.6

More than once a week
Every day

14.3
14.3

Only once or twice
About once a year
A few times each year

24.1
3.4
48.3

About once a month
More than once a week

10.3
13.8

During the evening
During the day
Frequently during
the day and night

42.9
42.9
14.3

During the evening
During the day
Frequently during
the day and night

79.3
6.9
13.8

MDMA

18.68 (1.87)

4

43

Only once or twice
About once a year
A few times each year
About once a month
About once a week

42.9
7.1
25
21.4
3.6

During the evening

Ketamine

18.62 (2.24)

5

44

Only once or twice
About once a year
A few times each year

44.1

During the evening
During the day
Frequently during
the day and night

About once a month
About once a week
More than once a week
Every day

8.8
14.7
2.9

mean (n=86), more than 1 S.D. below the mean
(n=95), and those around the mean (n=351). The
group diﬀerences on the CEQ were examined using a
series of one-way ANOVAs [means (and standard
deviations)] : Pleasurable Experiences [High 50.49
(11.01), Mean 46.30 (10.85), Low 44.23 (11.68)] ; Psychosis-Like Experiences [High 61.40 (16.88), Mean
50.72 (16.26), Low 42.42 (13.44)] ; After-Eﬀects [High
31.74 (11.15), Mean 26.34 (9.64), Low 22.08 (7.82)]. The
p value required to be reached for this analysis was
0.016. There was a signiﬁcant eﬀect of psychosis
proneness group on all the subscales from the CEQ.
For the Pleasurable Experiences subscale [F(2, 529)=
7.66, p=0.001], the High group reported more than the
Mean (p=0.007) and the Low (p=0.001) psychosis
proneness groups. All the three groups scored signiﬁcantly diﬀerent from one another on the PsychosisLike Experiences subscale [F(2, 529)=32.27, p<0.001]
at above the 0.001 % level of signiﬁcance. For the AfterEﬀects subscale [F(2, 529)=22.86, p<0.001], the High
and Mean groups and Low and High groups diﬀered
at above the 0.001 % level, while the Mean and Low
diﬀered signiﬁcantly from one another at the 0.001 %
level.

29.1

100

87.9
6.1
6.1

Psychometric properties of the CEQ
All the items from the CEQ were entered into an exploratory PCA with data from 532 participants who
had used cannabis at least once in their lifetime. From
examination of a scree plot of the eigenvalues for the
data, it seemed that four components would appropriately explain the data. The PCA was performed
with an oblique rotation to allow the components to
correlate. The analysis accounted for 47.5 % of the total
variance. The items from the After-Eﬀects subscale all
loaded onto one component, and as these items are examining the period following the high from cannabis,
unlike the rest of the items, it seemed appropriate to
enter the After-Eﬀects items in a separate analysis.
Immediate eﬀects of cannabis
The PCA was repeated with the After-Eﬀects items
removed. From examining a scree plot it seemed that
two or three components described the data. The third
component comprised four items and only contributed 5.52 % to the total variance. Additionally,
when the internal consistency of the items were examined, Cronbach’s a only reached 0.57. Therefore,
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the two-component solution was judged to be most
eﬀective explanation of the data. The items are presented in Table 2. Loadings above 0.3 were taken to
be signiﬁcant and a simple solution was sought
with the highest loading being taken as signiﬁcant
if an item loaded onto both components. The Pattern
Matrix was used to determine the pattern of loadings because this matrix presents the loadings independent of the correlation between the two
components.
The solution accounted for 39.2 % of the total variance, with Component 1 contributing 25.2 % and Component 2 14.0 % of the variance. Only the item of
‘Sleepy ’ did not load signiﬁcantly on to either of the
components. Component 1 had a Cronbach’s a coefﬁcient of 0.93 and Component 2 had an a of 0.88 ;
therefore, both the components display more than
adequate internal consistency. The items on Component 1 contain many of the symptoms that were previously on the Psychosis-Like Experiences subscale.
The items on Component 2 seem to represent largely
pleasant experiences, which may be an excessive
of everyday occurrence of emotions. The items on
Component 1 can be characterized by the title
‘Paranoid-dysphoric Experiences ’ whereas Component 2 items are explained by the term ‘Euphoric Experiences ’.
After-Eﬀects
The items from the After-Eﬀects subscale were entered
into a separate PCA. Examination of a scree plot determined that the items would be adequately explained by extracting two components from the data.
An oblique rotation was used to allow the components
to correlate with one another. As with the previous
analysis, the Pattern Matrix was used to determine
which items loaded signiﬁcantly onto each component, loadings above 0.3 were taken as signiﬁcant and
a simple solution was sought. The results from the
analysis are presented in Table 3.
The PCA explained 64.5 % of the variance, with
Component 1 accounting for 51.9 % of the variance
and Component 2 contributing 12.5 % of the total
variance. Cronbach’s a coeﬃcients demonstrated that
the components had adequate internal consistency
(Component 1, 0.92 ; Component 2, 0.80). However,
collapsing both components into the original AfterEﬀects subscale still produced an a value of 0.92.
The items on Component 1 can be characterized as
‘Amotivational after-eﬀects ’ whereas Component 2
items can be appropriately labelled ‘ Psychosis-like
after-eﬀects ’.
To examine the intercorrelations between the subscales, two-tailed levels of signiﬁcance are presented

Table 2. The item loadings for the two components extracted
from the items comprising immediate responses to cannabis
Component 1
All powerful
Angry
Anxious
Auditory hallucinations
Being relaxed
Compulsive
Deluded
Depressed
Disturbed in your thinking
Ecstatic
Energized
Enhanced perceptual
awareness
Excited
Fearful
Fearful that you are
going mad
Feeling happy
Feel more creative
Full of ideas
Full of plans
Laid back
Lethargic
Looking for excitement
Losing sense of reality
Nervy
No longer knowing yourself
Things not feeling right
on your skin
Obsessive
Out of body experiences
Paranoid
Powerful
Rapid ﬂow of thoughts
Reduced level of
consciousness
Religious
Sad
Sentimental
Slowing of time
Speech becomes slurred
Threatened by an
unknown force
Uncomfortably sleepy
Understand the world better
Visual hallucinations

Component 2

0.177
0.527
0.777
0.546
x0.281
0.569
0.662
0.646
0.770
x0.036
x0.127
0.172

0.478
x0.074
x0.073
0.177
0.571
0.129
0.111
x0.078
x0.046
0.696
0.488
0.634

x0.131
0.779
0.732

0.581
x0.123
x0.015

x0.271
0.040
0.128
0.074
x0.145
0.480
0.027
0.661
0.781
0.713
0.588

0.639
0.757
0.742
0.681
0.489
x0.032
0.638
0.084
x0.069
x0.033
0.091

0.683
0.356
0.719
0.062
0.512
0.615

0.034
0.210
x0.019
0.506
0.366
x0.054

0.157
0.607
0.108
0.530
0.501
0.654

0.364
x0.072
0.493
0.056
x0.046
0.034

0.533
0.143
0.522

x0.166
0.697
0.081

Bold values indicate factor loadings taken to be signiﬁcant.

for the Pearson’s correlation coeﬃcients in order to
take a conservative approach, considering the size
of the sample being used. The intercorrelations
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Table 3. The component loadings for the items from the
After-Eﬀects subscale from the Cannabis Experiences
Questionnaire (CEQ)
Component 1
Disinhibited
0.297
Don’t want to do anything
0.889
Generally slowed down
0.949
Loss of motivation
0.916
Thinking slowed down
0.816
Cannot concentrate
0.779
Slowing of time
0.494
Paranoid without reason x0.052
Suspicious without reason x0.082
Felt depersonalized
0.035
Cannot remember events
0.310
Have reduced attention
0.675

Component 2
0.360
x0.095
x0.125
x0.043
0.013
0.100
0.322
0.925
0.952
0.722
0.421
0.179

Bold values indicate factor loadings taken to be signiﬁcant.

between the subscales were as follows (Pearson’s r) :
Amotivational after-eﬀects signiﬁcantly correlated
with Psychosis-like after-eﬀects (0.63), Euphoric (0.18)
and Paranoid-dysphoric (0.54) experiences ; Psychosislike after-eﬀects signiﬁcantly correlated with Euphoric
(0.25) and Paranoid-dysphoric (0.69) experiences ;
and Paranoid-dysphoric and Euphoric experiences
(0.16) signiﬁcantly correlated with one another. All
the correlations are signiﬁcant above the 1 % level.
Relationship between schizotypy and CEQ factors
As reported above, we have shown that those who
score highly on the psychosis score signiﬁcantly different from Mean or Low schizotypes on their reported experience with cannabis. A similar analysis
was performed with the PCA-derived subscales for
the CEQ. As before, participants were grouped according to being ¡1 S.D. or around the mean on the
total score on the SPQ. The ANOVAs were signiﬁcantly diﬀerent for the four subscales. However, the
F values were larger for the subscales for the immediate and after-eﬀects that had the psychotic items on.
Scheﬀé post-hoc comparisons were performed to determine which groups scored signiﬁcantly diﬀerent
from one another on the subscales. The means (and
standard deviations) for this analysis were : Paranoiddysphoric subscale [High 59.44 (16.72), Mean 48.74
(16.21), Low 40.42 (13.69)] ; Euphoric subscale [High
45.07 (10.76) ; Mean 40.94 (10.39) ; Low 39.42 (11.05)] ;
Amotivational after-eﬀects [High 20.02 (7.36), Mean
17.57 (6.98), Low 14.75 (5.96)] ; and Psychosis-like
after-eﬀects [High 11.70 (4.80), Mean 8.77 (3.71), Low
7.34 (2.62)]. For the Paranoid-dysphoric Experiences
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subscale [F(2, 529)=32.52, p<0.001], the groups all
diﬀered signiﬁcantly from one another above the 1 %
level of signiﬁcance. On the Euphoric Experiences
subscale [F(2, 529)=7.17, p=0.001] the High and
Mean (0.005) and the High and Low (0.002) diﬀered
signiﬁcantly from one another. The High and Mean
(0.012), High and Low (>0.001) and Mean and Low
(0.002) groups diﬀered signiﬁcantly from one another
on the Amotivational after-eﬀects subscale [F(2, 529)=
13.53, p<0.001]. For the Psychosis-like after-eﬀects
subscale [F(2, 529)=32.32, p<0.001], the Mean and
Low groups diﬀered from one another with a signiﬁcance value of 0.004, but the other groups diﬀered at
above the 0.001 % level of signiﬁcance.

Discussion
Cannabis use and schizotypy
There was no relationship between schizotypy score
and frequency of cannabis use nor the age of ﬁrst use
of cannabis. However, those who had smoked cannabis
at least once had higher scores on the Disorganized
dimension from the SPQ than those who had not
smoked cannabis. There was also a trend for those
current cannabis users to have higher scores on the
Disorganized dimension compared to previous users.
This was against our initial hypothesis that schizotypy
status would not be related to patterns of cannabis use.
Two previous studies have reported a relationship
between cannabis use and disorganized schizotypal
symptoms (Dumas et al. 2002 ; Schiﬀman et al. 2005).
The Disorganized dimension of the SPQ comprises
items that measure odd behaviour and odd speech.
Dumas et al. (2002) reported that gender diﬀerences
could account for the relationship between disorganized schizotypal trait and cannabis use. Therefore,
gender was placed in an ANOVA as a covariate, with
cannabis use as the independent variable and the
Disorganized subscale as the dependent variable.
However, the diﬀerence between those who had and
those who had not smoked cannabis remained signiﬁcant. The relationship between disorganized schizotypal traits and cannabis use deserves further study
especially because Schiﬀman et al. (2005) not only replicated these ﬁndings but also reported that the disorganized symptoms preceded cannabis use. It is also
interesting that the two other recreational drugs
(speed and cocaine) that showed a lead to a signiﬁcant
diﬀerence on the Disorganized dimension from the
SPQ both elevate levels of dopamine in the brain.
Perhaps the disorganized features of schizotypy are
particularly sensitive to ﬂuctuations in dopamine, even
at levels that may not produce unusual perceptual
experiences. The disorganized features of schizotypy
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are relatively underinvestigated, with greater emphasis being placed on the positive features ; however, the
current data suggest they may warrant further investigation.
Schizotypy and cannabis experiences
The PCA for the immediate eﬀects from cannabis
use produced two components, Paranoid-dysphoric
Experiences and Euphoric Experiences, both with
high internal consistency. The items on each subscale are reﬂected by their title, with the symptomatic eﬀects from cannabis use appearing on the
Paranoid-dysphoric Experiences subscale and the
more expansive experiences from cannabis use characterizing the Euphoric Experiences subscale. The internal consistency scores for the two subscales for
the after-eﬀects from cannabis use also had high a
values, although when they were combined, the
Cronbach’s a coeﬃcient for the after-eﬀects items was
equally as high. The two subscales produced were :
Amotivational after-eﬀects and Psychosis-like aftereﬀects.
Using the original subscales reported in Barkus et al.
(2006), participants with high schizotypy scores reported higher levels of subjective experiences on all
factors. The previous ﬁndings were largely replicated,
with the exception that the high schizotypes also reported higher levels of pleasurable experience, although the mean diﬀerence between the three groups
is small and considerably less than that shown for
psychosis-like experiences.
However, examining the schizotypy group diﬀerences on the new subscales demonstrated an interesting ﬁnding. Although the ANOVAs were all
signiﬁcant for the four new subscales, the largest
F values and diﬀerentiation between the three groups
can be seen on the subscales that contain the psychotic
symptoms, that is the Paranoid-dysphoric from the
immediate experiences and the Psychosis-like aftereﬀects from cannabis use. These results suggest that,
although there appears to be no psychometric advantage to the two components that comprise the
after-eﬀects experiences, it may be informative from a
hypothesis testing perspective to use the PCA-derived
subscales.
From the results in this paper it is possible to
argue for a causal relationship between cannabis
use and psychotic symptoms in those who express
high schizotypy. We cannot comment on associations
with diagnosable psychotic disorders as these data
were not available for the sample collected. In line
with Henquet et al. (2005), those with high schizotypy
seemed to be more sensitive to the eﬀects from
cannabis use because they scored higher on all

the subscales from the CEQ. In the light of previous research, perhaps our results point towards dopamine sensitization as being a possible mechanism
for high schizotypes having more experiences with
cannabis per se and particularly more psychomimetic
eﬀects.
Validation of cannabis experiences as expression of
psychosis proneness
It is now accepted that the psychotic experiences reported in those who score highly on schizotypy measures are qualitatively similar to those reported in
patient samples (e.g. Honig et al. 1998). A similar argument could be applied to the clinical relevance and
validity for the psychotic experiences associated with
cannabis use. There is emerging clinical and experimental evidence to suggest that the psychotic symptoms that result from cannabis use are of clinical
relevance and may indicate risk of underlying psychopathology. The administration of the psychoactive
substance D9-THC to healthy volunteers was reported
to induce psychotic-like symptoms when given intravenously (D’Souza et al. 2004) and a psychosis
prodrome-like state when giving orally (Koethe et al.
2006). Sensitivity to the eﬀects of D9-THC is modulated
by psychometric psychosis liability and genetic polymorphism (COMT) determined dopamine turnover in
the cortex (Henquet et al. 2006). Taken together, these
studies point to the manipulation of dopamine by D9THC underpinning the psychotic experiences associated with recreational cannabis use and also indicate
that D9-THC would be a useful experimental model of
psychosis. From a clinical perspective, 47.1 % of those
seeking help for cannabis-induced psychosis were diagnosed with schizophrenia-spectrum disorder 1 year
after initial presentation (Arendt et al. 2005), suggesting that psychotic responses to cannabis may also have
some predictive validity.
Limitations
The data from the current study were self-reported
and collected using the internet. Remote collection of
data has been questioned in terms of its validity and
reliability. The population means for the SPQ in the
current sample are similar to those reported by Raine
(1991). Additionally, we have previously used internet
data collection and validated responses at interview
(e.g. Barkus et al. 2007). Although participants had the
option to provide an email address (to take part in
later phases of the study), the results were largely
anonymous, which should have encouraged honest
reporting of schizotypal traits and cannabis experiences. Self-reported rates of cannabis use have been
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shown to be highly correlated with biological measures (Fendrich et al. 2004). It was also made clear to
participants there would be no consequences for any
reported drug use. The high internal consistency
values for the CEQ subscales suggest that random responding was not taking place, or at least if it did, it
did not inﬂuenced the results. Internet data collection
permits the accumulation of a large number of responses in a relatively short period of time, which
holds both for psychometric validation and for identifying individuals who score at the extremes of a personality trait. Extreme high-scoring schizotypes are
more likely to approach remote data collection methods. There is a possibility that such individuals would
have high levels of social anxiety and therefore avoid
face-to-face interactions but a computer interface
would appear more controllable and less intimidating
to them.
The validation of the items on the CEQ to date has
taken place in relatively young student samples.
Therefore, the measure needs to be considered in a
more heterogeneous general public sample next. In
particular, the patterns of cannabis use may be diﬀerent in a general population sample because its use may
have greater impact on daily life outside a student
culture. Additionally, although the predictive value of
the CEQ has been speculated upon here, this needs to
be formally tested in diﬀerentiating schizophreniaspectrum disorder patients from other clinical groups,
as well as being examined in terms of predicting
transition to psychosis in prodrome samples.
The current study has replicated previous ﬁndings
of an association between schizotypy and psychopathological experiences and increased after-eﬀects
from recreational cannabis use. The new PCA-derived
subscales suggest that it is the psychotic-like experiences in response to cannabis use that diﬀerentiate
high-scoring schizotypes from mean- and low-scoring
schizotypes most strikingly. The results suggest that
the CEQ is a valid and useful instrument to further
elucidate the relationship between cannabis and psychosis.
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